



A**B**

Figure S1: MUC4 inhibition induced a decrease of miR-210-3p relative level in 647-V cells. (A) qRT-PCR analysis of miR-210-3p relative expression was performed in mock and MUC4-KD 647-V cells. Expression of miR-210 was evaluated according to the $2^{-\Delta\text{Ct}}$ method ($\Delta\Delta\text{Ct} = (\text{Ct miR-210} - \text{Ct RNU48})$). **(B)** Western blotting analysis of MUC4 and β -actin expression in 647-V mock and MUC4-KD cells.

A




Figure S2: MUC4 and miR-210 expression levels are correlated in TCGA-PAAD dataset. MiR-210 (RPM) and MUC4 RNA (RSEM) relative expression levels were extracted using www.linkedomics.org, where after Spearman correlation test were performed.



A**B**

Figure S3: Evaluation of miR-210 expression in transient and stable expression cell models. qRT-PCR analysis of miR-210-3p relative expression in PANC89, PANC1 and MIA PaCa-2 pancreatic cancer cells 96 h post miR-210 transfection (A) and in PANC1 stably transfected with miR-210-3p, anti-miR-210-3p and miR-scramble, anti-miR-control (PANC-1/AAVS1) (B).




Figure S4: Full pictures of Western blots. (A) MUC4 and β -actin uncropped western blots from figure 1 and S1. (B) NF- κ B p 50 and β -actin uncropped western blots from figure 3. (C) MUC4 and β -actin uncropped western blots from figure 4. (D) Akt, cyclinD1 and β -actin uncropped western blots from figure 7.